Cardiovascular · Year 1 · from Cardiovascular
Case 3: Deep Vein Thrombosis and Pulmonary Embolism - Virchow's Triad
Clinical Image
Source: Wikimedia Commons - DVT - CC BY-SA 3.0
Patient Presentation
A 45-year-old woman presents to the emergency department with 3 days of left leg swelling and pain. Yesterday she developed shortness of breath with exertion. She returned from a 12-hour flight from Australia 5 days ago. She also mentions she was started on hormone replacement therapy 3 months ago for menopausal symptoms.
Demographics
- Age: 45 years
- Sex: Female
- Past Medical History: Surgical menopause (hysterectomy 6 months ago for fibroids)
- Medications: Estrogen replacement therapy
- Social History: Occasional alcohol, no smoking
Chief Complaint
Left leg swelling and pain for 3 days, shortness of breath for 1 day
Physical Examination
- Blood pressure: 118/76 mmHg
- Heart rate: 105 bpm
- Respiratory rate: 22/min
- Oxygen saturation: 92% on room air
- Left lower extremity:
- Circumferential swelling (3 cm larger than right at mid-calf)
- Warmth and erythema
- Tenderness along the medial thigh
- Positive Homan's sign (nonspecific)
- Pitting edema
- Cardiovascular: Tachycardic, regular rhythm
- Respiratory: Clear to auscultation, mild tachypnea
Workup
- Wells Score for DVT: 4 (moderate-high probability)
- Wells Score for PE: 4.5 (moderate probability)
- D-dimer: 3,450 ng/mL (elevated)
- Compression ultrasound: Non-compressible left common femoral and popliteal veins with echogenic thrombus
- CT pulmonary angiography: Bilateral segmental pulmonary emboli; no RV strain
- Troponin: Mildly elevated
- BNP: 180 pg/mL (mildly elevated)
- Echocardiography: Normal RV size and function
Diagnosis
Proximal Deep Vein Thrombosis with Submassive (Intermediate-Low Risk) Pulmonary Embolism
Treatment
- Anticoagulation initiated immediately:
- Options: LMWH bridge to warfarin, or DOAC monotherapy (rivaroxaban or apixaban)
- Duration: Minimum 3 months; extended duration consideration given provoked by modifiable factors
- Discontinue estrogen therapy (major risk factor)
- Risk stratification: Intermediate-low risk PE (positive biomarkers but no RV dysfunction) - does not require thrombolysis
- Graduated compression stockings for DVT symptoms
- Early ambulation (bed rest not required)
- Outpatient follow-up; consider IVC filter only if anticoagulation contraindicated
Physiological Principles Demonstrated
- Virchow's triad: This patient demonstrates all three components:
- Stasis: Prolonged immobility during long-haul flight
- Endothelial injury: Recent surgery (hysterectomy)
- Hypercoagulability: Exogenous estrogen therapy
- DVT and PE connection: Over 90% of pulmonary emboli originate from lower extremity or pelvic DVT, emphasizing that DVT and PE are the same disease process.
- Risk stratification: Not all PEs require aggressive intervention. Hemodynamic stability and RV function determine management intensity.
- Provoked vs. unprovoked: This VTE is provoked by identifiable transient risk factors (travel, estrogen), informing duration of anticoagulation and recurrence risk.